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Transmission of Chronic Myeloid Leukemia
through Peripheral-Blood Stem-Cell Transplantation
to the editor: Although secondary cancer is a well-
established long-term complication of hematopoi-
etic stem-cell transplantation,1 the transmission
of hematologic cancers through marrow or solid-
organ transplantation is exceptional.2 Moreover,
to our knowledge, it has not been reported after
peripheral-blood stem-cell transplantation.
A nine-year-old African child received a diag-
nosis of sickle cell disease (hemoglobin SC) in
1991. Between 1991 and 2001, he had multiple vaso-
occlusive crises, despite hydroxyurea therapy. He
was referred to us at the age of 19 years for trans-
plantation of peripheral-blood stem-cells from an
HLA-identical brother who was heterozygous for
sickle cell disease.3,4 Before peripheral-blood stem-
cell mobilization with a six-day regimen of granu-
locyte colony-stimulating factor at a dose of 10 µg
per kilogram of body weight, the donor’s physical
examination and hematologic studies were unre-
markable, except for a slight inversion of the neu-
trophil:lymphocyte ratio, as is frequently observed
in African persons (Table 1).
After conditioning with oral busulfan (16 mg per
kilogram), intravenous cyclophosphamide (200 mg
per kilogram), and antithymocyte globulin (90 mg
per kilogram), the patient received a CD34-select-
ed peripheral-blood stem-cell graft containing
4¬106 CD34+ cells per kilogram and 0.01¬106
CD3+ cells per kilogram. Prophylaxis against graft-
versus-host disease was carried out with cyclospor-
ine alone. The immediate post-transplantation
course was complicated by cyclosporine-associat-
ed pancreatitis that resolved after the withdrawal
of cyclosporine on day 21, and the patient was dis-
charged on day 35. Neither acute nor chronic graft-
versus-host disease developed.
The results of bone marrow evaluation on day
100 were normal, with more than 95 percent chi-
merism, but the karyotype showed a Philadelphia
chromosome in 9 of 31 metaphases. Fluorescence
in situ hybridization analysis confirmed the BCR-
ABL rearrangement in 14 percent of marrow cells.
Bone marrow evaluation in the donor showed chron-
ic-phase chronic myeloid leukemia with the Phila-
delphia chromosome in 95 percent of the cells. The
recipient was treated with STI571, and a complete
cytogenetic and molecular remission was achieved
three and six months later, respectively. Now, more
than one year after the transplantation, the patient
is well, without any sign of chronic graft-versus-host
disease, and is heterozygous for sickle cell disease
(the status of the donor). The donor initially received
interferon alfa but did not tolerate it and then re-
ceived STI571; a complete cytogenetic response was
achieved, but a complete molecular response has
not yet occurred.
Transmission of acute myeloid leukemia as well
as T-cell lymphoma through bone marrow trans-
plantation has been reported previously.2,5 How-
ever, this case shows that chronic myeloid leuke-
mia can also be transmitted through transplantation
of peripheral-blood stem cells from a donor with
no sign of chronic myeloid leukemia in the periph-
eral blood. This raises the issue of routine bone mar-
row and karyotype examination in donors of pe-
ripheral-blood stem cells.4 However dramatic such
cases are, it would be costly and ineffective, as well
* ND denotes not done.
† The normal range is 200 to 440 U per liter.
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Platelets (¬10¡9/liter) 298 234 245
Lactate dehydrogenase† 279 ND 492
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as uncomfortable for the donor, to carry out these
investigations systematically in all donors.
Frederic Baron, M.D., Ph.D.
Marie-Françoise Dresse, M.D.
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